HeimCGEN • NASDAQ
add
Compugen Ltd
1,52 $
Fyrir opnun:(0,66%)-0,0100
1,51 $
Lokað: 27. nóv., 08:00:31 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
1,41 $
Dagbil
1,37 $ - 1,54 $
Árabil
0,62 $ - 3,03 $
Markaðsvirði
136,10 m. USD
Meðalmagn
262,37 þ.
V/H-hlutf.
79,29
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 17,13 m. | — |
Rekstrarkostnaður | 9,04 m. | -14,99% |
Nettótekjur | 1,28 m. | 112,95% |
Hagnaðarhlutfall | 7,45 | — |
Hagnaður á hvern hlut | 0,01 | 109,09% |
EBITDA | 4,62 m. | 143,92% |
Virkt skatthlutfall | 77,92% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 112,71 m. | 95,99% |
Heildareignir | 123,52 m. | 82,69% |
Heildarskuldir | 63,03 m. | 338,18% |
Eigið fé alls | 60,49 m. | — |
Útistandandi hlutabréf | 89,54 m. | — |
Eiginfjárgengi | 2,07 | — |
Arðsemi eigna | 9,62% | — |
Ávöxtun eigin fjár | 18,01% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 1,28 m. | 112,95% |
Handbært fé frá rekstri | — | — |
Reiðufé frá fjárfestingum | — | — |
Reiðufé frá fjármögnun | — | — |
Breyting á handbæru fé | — | — |
Frjálst peningaflæði | — | — |
Um
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
Framkvæmdastjóri
Stofnsett
10. feb. 1993
Vefsvæði
Starfsfólk
68
